INVESTMENTS IN OUR THREE FOCUS AREAS:
BIOTECHNOLOGY, ADVANCED NUTRITION AND DIGITAL HEALTH.
Vedanta is charting a New World of Medicines by developing a new category of therapies for immune-mediated diseases based on a rationally-defined consortia of human microbiome-derived bacteria.
It has four clinical-stage programs in development for solid tumors, high-risk CDI, food allergy, and IBD, and one preclinical discovery program for the prevention of infection and recurrence of several multi-drug resistant organisms.
Aleph Farms is an Israeli food technology and tissue engineering company that cultivates steaks from non-GMO cells without any harm to animals and with a significantly reduced impact to the environment. With their unique and disruptive cell-based strategy for cultivation of quality whole beef steaks, they preserve the traditional nutrition, texture and taste that consumers love.
Leader of the global sustainable food ecosystem, their mission is to feed the world while preserving the planet.
Evolve Biosystems is an advanced nutrition company solving gut dysbiosis prevalent in newborn infants. Evolve platform delivers products that restore, and maintain a healthy gut microbiome for preterm and term infants through hospital and consumer channels.
The company is a spin-out from the Foods for Health Institute (FFHI) at the University of California, Davis and builds on a decade of expertise in the partnership between the infant gut microbiome and breast milk components.
MIRAI FOODS is a Switzerland-based cellular agriculture company, dedicated to providing delicious, high quality cultivated meat, at a fair price. Better for the planet and the animals, and healthier for people.
By using their proprietary process which does not rely on genetic or chemical manipulation of cells, their first product will be beef, as it has the largest greenhouse gas footprint.
Headquartered in South San Francisco, Cellares is creating the future of cell therapy manufacturing and accelerating access to life-saving cell therapies. Its proprietary platform—The Cell Shuttle—combines fully automated manufacturing and workflow customization, features highly sought by leading biopharma companies, academic research centers, and CDMOs.
Their one-of-a-kind solution is designed to overcome the limitations associated with manufacturing so cell therapies become more affordable and widely available to patients in need.
MaaT Pharma is a clinical stage oncology company located in Lyon and an industry leader in gut microbiome ecosystem restoration therapies to improve patients’ survival outcomes in life-threatening diseases such as acute myeloid leukemia and GvHD.
Products are supported by MaaT’s powerful discovery and analysis platform, GutPrint®, which evaluates drug candidates, determines novel disease targets and identify biomarkers for microbiome-related conditions.
Abintus Bio, Inc. is a San Diego-based, preclinical stage gene therapy company focused on the discovery and development of a portfolio of first-in-class, product candidates that are designed to directly reprogram immune cells from within their native environment.
Founded in 2020, Abintus is using its proprietary technology to reprogram a patient’s immune cells in vivo – without the need to remove them. The approach will reduce costs, save time and has the potential to bring significant clinical benefits to more people.
Ukko is a biotechnology company using cutting edge technologies in immunology, computational biology, and protein engineering to improve the lives of millions that suffer from food allergies and disorders.
Founded in 2016 with offices and labs in Tel Aviv and Palo Alto, Ukko is developing non-immunogenic gluten proteins for baked goods and redesigning the major immunogenic peanut proteins to provide patients with a safe and efficacious desensitization therapy.
Tropic Biosciences is a UK-based pioneering agricultural-biotechnology company dedicated to the development of high-performance varieties of tropical crops.
Their innovative and proprietary gene-editing technology is first being applied to banana and coffee which face a wide range of critical challenges, from diseases and pests to climate change. Tropic is working closely with growers to address these major issues and promotes unmet nutritional needs, positive grower economics and sustainable environmental practices.
COMPASS Pathways is a life sciences company dedicated to developing new evidence-based therapies that will help patients and their families suffering with mental illness and increase their wellbeing.
Founded in 2016, their first major initiative is developing psilocybin with the highest regulatory standards, through late-stage clinical trials in Europe and North America for patients with treatment-resistant depression.
Beyond Meat is one of the fastest growing food companies in the United States, offering a portfolio of revolutionary plant-based meats. They create meat-like products directly from plants, an innovation that enables consumers to experience the taste, texture and other sensory attributes of popular animal-based meat.
We benefited from the success of their May 2nd 2019 IPO, which reflects market trust and consumer’s excitement for meat analogs.
Siemens Healthineers’s IPO was a major highlight and financial reward for investors.
The company is unparalleled in its purpose to enable and empower healthcare providers on their journey towards expanding precision medicine, transforming care delivery, and improving patient experience. All enabled by cutting edge digital healthcare.
Founded in 2016, Forward is a US-based concierge medical service redesigning the way healthcare is delivered using all the technologies healthcare neglected such as sensors, mobile, and AI.
By offering a health membership that combines access to a personal doctor with the latest technology, Forward is providing a new health experience.
Five Seasons Ventures is a VC fund investing in food product and process innovation. From alternative proteins, to personalised nutrition, from natural ingredients to new models of food distribution, they back food tech entrepreneurs throughout the food value chain.
With offices in Paris and Bologna, their team combines over 20 years of successful high tech-investing with over 20 years of deep food industry experience. They are pioneer investors in this sector and proudly put the word “FoodTech” in venture capital in Europe.
Incredible Foods developed patent-protected all-natural coatings inspired by the skin of a grape. These 100% plant-based skins act as protective barriers and deliver powerful taste and flavor profiles, enabling the creation of unique consumer health products.
Ideally positionned to capture the trend towards healthier foods with no preservatives and no artificial sweeteners, the company’s brand “Perfectly Free” offers a new category of fruit snacks packed with nutrition in a natural, fun and practical way.
Evox Therapeutics is a privately held, Oxford-based biotechnology company focused on harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes.
Evox is engineering exosomes to enable a wide variety of drugs to reach previously inaccessible tissues and compartments, such as crossing the blood brain barrier to deliver drugs to the CNS, intracellular delivery of biologics, and extra-hepatic delivery of RNA therapeutics.
Tiba Biotech emanated in 2017 from a four-year multilab research initiative between the Massachusetts Institute of Technology’s Koch Institute, the Whitehead Institute, and Boston Children’s Hospital.
With our international collaborators and strategic partners, Tiba (the Swahili word for “treatment” or “cure”) is leveraging a revolutionary replicon RNA technology platform to develop safer, affordable vaccines for both human and animal health.